YuanBio Venture Capital

YuanBio Venture Capital is a Suzhou-based Chinese venture firm focused on biotech and pharmaceutical therapeutics, supporting early- and growth-stage life sciences companies primarily within China. The firm sits in the specialized life sciences segment of Chinese venture, where Suzhou’s biotech cluster provides operational and scientific anchoring. Limited public information is available on individual partners or a published investment thesis in English-language sources, but the focus on biotech and pharma signals deep specialization in regulated drug and therapeutic development rather than digital health or software-led businesses.

Check sizes are in the five to twenty-five million dollar range, with deployment across seed, Series A, and Series B stages. China is the primary geographic focus, with portfolio companies typically headquartered domestically and engaging with Chinese regulatory pathways including NMPA review for therapeutics. Multi-stage capacity within early- to mid-stage rounds means YuanBio can serve as a serious lead or co-lead in financings that require domain-specific underwriting, which matters in biotech where capital intensity and regulatory complexity demand specialized investors.

For founders, YuanBio is most relevant to biotech and pharma teams developing therapeutics, biologics, or pharmaceutical platforms with meaningful Chinese market or development components. Strong scientific founders, clear development plans aligned to Chinese regulatory realities, and credible CMC and clinical trial strategies will resonate. Founders pitching digital health, software, or services will not find a fit. Companies should be prepared to discuss integration with the Chinese biotech ecosystem including CROs, manufacturing capacity, and downstream strategic or capital sources, since these dynamics meaningfully shape biotech outcomes in China.